{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.7","upperLimit":"18.8","value":"17.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"PFS will be measured in all participants. Survival and PFS functions were estimated using the Kaplan-Meier method. The Cox regression model was used to assess the following plausible risk factors for OS and PFS: age, isotype, number of cycles of therapy, and cytogenetic profile.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).\n\nMK-3475: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.\n\nPomalidomide: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days\n\nDexamethasone: Dexamethasone is given at 40 mg orally weekly","id":"OG000","title":"Pomalidomide, Dexamethasone & MK-3475"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"PFS assessments will take place after starting study therapy with MD-3475 and will continue until the start of a new anti-neoplastic therapy, disease progression, death, or the end of study up to an average of 24 months.","title":"Time to Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}